JP2008001722A - サイトカインおよび造血因子の内因性産生増強因子とその利用方法 - Google Patents

サイトカインおよび造血因子の内因性産生増強因子とその利用方法 Download PDF

Info

Publication number
JP2008001722A
JP2008001722A JP2007238577A JP2007238577A JP2008001722A JP 2008001722 A JP2008001722 A JP 2008001722A JP 2007238577 A JP2007238577 A JP 2007238577A JP 2007238577 A JP2007238577 A JP 2007238577A JP 2008001722 A JP2008001722 A JP 2008001722A
Authority
JP
Japan
Prior art keywords
endogenous production
glutathione disulfide
cytokines
methods
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007238577A
Other languages
English (en)
Other versions
JP2008001722A5 (ja
Inventor
Mark Borisovich Balazovsky
ボリソビチ バラツォフスキィ マルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectar Biosciences Inc
Original Assignee
Novelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU95120403/14A external-priority patent/RU2089179C1/ru
Application filed by Novelos Therapeutics Inc filed Critical Novelos Therapeutics Inc
Publication of JP2008001722A publication Critical patent/JP2008001722A/ja
Publication of JP2008001722A5 publication Critical patent/JP2008001722A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

【課題】内因性のサイトカインおよび造血因子産生を誘導することができる活性物質、および当該物質と／あるいはその誘導体と、その活性のエキステンダーや／もしくはエンハンサーあるいはモジュレーターの有益な組み合わせをそれを必要としている個体あるいは対象に提供すること。
【解決手段】サイトカインもしくは造血因子またはその両方に対する刺激を必要とする哺乳動物の体内に、治療効果を得るためにサイトカインおよび造血因子の内因性産生を刺激できるだけの時間、酸化型グルタチオン、医薬として許容される酸化型グルタチオン塩、医薬として許容されるグルタチオン誘導体またはこれらの混合物より選択された酸化型製剤の有効量を導入することを含んでなる、サイトカインおよび造血因子の内因性産生を刺激する方法。
【選択図】なし

Description

Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
Figure 2008001722
本発明の上記およびその他の目的、特徴および利点については、明細書と添付した図面を一緒に読むとさらに良く理解できいるだろう；
図１ａ，１ｂ、１ｃおよび１ｄはそれぞれ細胞ＨＬ−６０（対照あるいは本発明の調整品存在下）の蛍光フローサウイトメトリー分析、ヒトリンパ球（対照あるいは本発明の調整物存在下）の蛍光フローサウイトメトリー分析を示しており、実施例４の考察に記載の如く、培養した哺乳動物細胞でのアポトーシス−誘導標本活性の研究に関するものである。 図２はＧＳＳＧ塩および誘導体を作成したときの化学修飾のための箇所を印したＧＳＳＧ構造の図である。 図３，４，５，６，および７はＧＳＳＧを共有結合により：システアミン（Ｓ−チオエチルアミン−グルタチオンジスルフィド、図．３）；リポ酸（ビス−［６，８−チオオキタニル］１グルタチオンジスルフィド、図．４）；カルノシン（［ｂ−アラニル−ヒスチジル］１グルタチオンジスルフィド、図．５）、アデノシン（［９−β−Ｄ−リボフラノシルアデニル］１グルタチオンジスルフィド、図．６）、あるいはメチオニン（ビス−［２−アミノ−４−［メチルチオ］ブタノイル］１グルタチオンジスルフィド、図．７）に結合した化合物の図である。 図３，４，５，６，および７はＧＳＳＧを共有結合により：システアミン（Ｓ−チオエチルアミン−グルタチオンジスルフィド、図．３）；リポ酸（ビス−［６，８−チオオキタニル］１グルタチオンジスルフィド、図．４）；カルノシン（［ｂ−アラニル−ヒスチジル］１グルタチオンジスルフィド、図．５）、アデノシン（［９−β−Ｄ−リボフラノシルアデニル］１グルタチオンジスルフィド、図．６）、あるいはメチオニン（ビス−［２−アミノ−４−［メチルチオ］ブタノイル］１グルタチオンジスルフィド、図．７）に結合した化合物の図である。 図３，４，５，６，および７はＧＳＳＧを共有結合により：システアミン（Ｓ−チオエチルアミン−グルタチオンジスルフィド、図．３）；リポ酸（ビス−［６，８−チオオキタニル］１グルタチオンジスルフィド、図．４）；カルノシン（［ｂ−アラニル−ヒスチジル］１グルタチオンジスルフィド、図．５）、アデノシン（［９−β−Ｄ−リボフラノシルアデニル］１グルタチオンジスルフィド、図．６）、あるいはメチオニン（ビス−［２−アミノ−４−［メチルチオ］ブタノイル］１グルタチオンジスルフィド、図．７）に結合した化合物の図である。 図３，４，５，６，および７はＧＳＳＧを共有結合により：システアミン（Ｓ−チオエチルアミン−グルタチオンジスルフィド、図．３）；リポ酸（ビス−［６，８−チオオキタニル］１グルタチオンジスルフィド、図．４）；カルノシン（［ｂ−アラニル−ヒスチジル］１グルタチオンジスルフィド、図．５）、アデノシン（［９−β−Ｄ−リボフラノシルアデニル］１グルタチオンジスルフィド、図．６）、あるいはメチオニン（ビス−［２−アミノ−４−［メチルチオ］ブタノイル］１グルタチオンジスルフィド、図．７）に結合した化合物の図である。 図３，４，５，６，および７はＧＳＳＧを共有結合により：システアミン（Ｓ−チオエチルアミン−グルタチオンジスルフィド、図．３）；リポ酸（ビス−［６，８−チオオキタニル］１グルタチオンジスルフィド、図．４）；カルノシン（［ｂ−アラニル−ヒスチジル］１グルタチオンジスルフィド、図．５）、アデノシン（［９−β−Ｄ−リボフラノシルアデニル］１グルタチオンジスルフィド、図．６）、あるいはメチオニン（ビス−［２−アミノ−４−［メチルチオ］ブタノイル］１グルタチオンジスルフィド、図．７）に結合した化合物の図である。

Claims (1)

  1. 本明細書に記載されるような、サイトカインおよび造血因子の内因性産生増強因子とその利用方法。
JP2007238577A 1995-12-14 2007-09-13 サイトカインおよび造血因子の内因性産生増強因子とその利用方法 Pending JP2008001722A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (ru) 1995-12-14 1995-12-14 Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP09521965A Division JP2000515111A (ja) 1995-12-14 1996-12-10 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Publications (2)

Publication Number Publication Date
JP2008001722A true JP2008001722A (ja) 2008-01-10
JP2008001722A5 JP2008001722A5 (ja) 2009-01-29

Family

ID=26653679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP09521965A Withdrawn JP2000515111A (ja) 1995-12-14 1996-12-10 サイトカインおよび造血因子の内因性産生増強因子とその利用方法
JP2007238577A Pending JP2008001722A (ja) 1995-12-14 2007-09-13 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP09521965A Withdrawn JP2000515111A (ja) 1995-12-14 1996-12-10 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Country Status (8)

Country Link
EP (1) EP0869809B1 (ja)
JP (2) JP2000515111A (ja)
AT (1) ATE214936T1 (ja)
AU (1) AU1113097A (ja)
CA (1) CA2239874A1 (ja)
DE (1) DE69620233T2 (ja)
ES (1) ES2174124T3 (ja)
WO (1) WO1997021444A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923938A4 (en) * 1997-03-21 2004-01-02 Shiseido Co Ltd IMMUNOSTIMULANTS
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US6399372B1 (en) 1998-03-30 2002-06-04 I.D.M. Immuno-Designed Monocyte derived cells with immunostimulating properties, their preparation and uses
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
EP1596756A4 (en) * 2003-01-23 2009-11-11 Supernus Pharmaceuticals Inc MEANS TO INCREASE ABSORPTION
RU2482868C1 (ru) * 2011-12-30 2013-05-27 Общество С Ограниченной Ответственностью "Ива Фарм" Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний
CA2886556C (en) * 2012-09-28 2022-11-22 Kyowa Hakko Bio Co., Ltd. Agent for enhancing immunity containing glutathione
RU2545900C2 (ru) * 2013-05-07 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ диагностики апоптоза лимфоцитов
RU2540500C2 (ru) * 2013-05-07 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ прогнозирования ранней стадии апоптоза
RU2659161C1 (ru) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
CN114617899B (zh) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277619A (ja) * 1985-06-04 1986-12-08 Otsuka Pharmaceut Factory Inc 肝疾患治療剤
JPH04230698A (ja) * 1990-12-28 1992-08-19 Senju Pharmaceut Co Ltd 酸化型グルタチオンアルキルエステル

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277619A (ja) * 1985-06-04 1986-12-08 Otsuka Pharmaceut Factory Inc 肝疾患治療剤
JPH04230698A (ja) * 1990-12-28 1992-08-19 Senju Pharmaceut Co Ltd 酸化型グルタチオンアルキルエステル

Also Published As

Publication number Publication date
DE69620233T2 (de) 2002-11-14
EP0869809A1 (en) 1998-10-14
ATE214936T1 (de) 2002-04-15
AU1113097A (en) 1997-07-03
ES2174124T3 (es) 2002-11-01
EP0869809B1 (en) 2002-03-27
CA2239874A1 (en) 1997-06-19
JP2000515111A (ja) 2000-11-14
WO1997021444A1 (en) 1997-06-19
DE69620233D1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
JP2008001722A (ja) サイトカインおよび造血因子の内因性産生増強因子とその利用方法
RU2314307C2 (ru) СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ
Danscher In vivo liberation of gold ions from gold implants. Autometallographic tracing of gold in cells adjacent to metallic gold
Davidovitch et al. Biochemical mediators of the effects of mechanical forces and electric currents on mineralized tissues
Kodicek et al. Biological activity of a polar metabolite of vitamin D3
Hakeda et al. Prostaglandin E2 stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells
Morita et al. The collagenolytic activity during root resorption of bovine deciduous tooth
ATE260931T1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
DK0500556T3 (da) Kompleks af aktivt stof til fremstilling af biologiske dele, især organer til levende væsner; fremgangsmåde til fremstillin
Nitisewojo et al. A comparison of some kinetic properties of soluble and bound lactate dehydrogenase isoenzymes at different temperatures
SE9801090L (sv) Odlingsmedium för animalceller
DE69328527D1 (de) Carboxypeptidase-ähnliches Protein aus Knochen und Verfahren zur dessen Herstellung
EP1395268B1 (en) A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
ATE61522T1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
Soong et al. Effects of electric fields on cytoskeleton of corneal stromal fibroblasts
Nawata et al. Local ion currents controlling the localized cytoplasmic movement associated with feeding initiation of Noctiluca
Servin et al. Pharmacokinetics of cysteine ethyl ester in rat
Krucher et al. Mitogenic activity of steroidogenesis-inducing protein (SIP) during hypoxic stress of human ovarian carcinoma cells
SU1458822A1 (ru) Способ исследовани естественного регионарного кровообращени
Willard et al. Alterations of two-dimensional electrophoretic maps in human peripheral blood lymphocytes induced by concanavalin A
Jakob et al. Is dipyridamole an angiogenic agent?
Bashey et al. Stimulation of collagen synthesis in embryonic chick skin by insulin
SU859442A1 (ru) Стимул тор активности митохондриальных и лизосомальных ферментов тканей животных
Jaros et al. The effect of pulsating electrical current on isolated nerve cells from the chick cerebral hemispheres cultivated in the rose chamber
Harrison et al. MONOCLONAL ANTIBODIES AGAINST RED BLOOD CELL ANTIGENS EXPRESSED AT DIFFERENT STAGES OF DEVELOPMENT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101222